Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of dapagliflozin in cardiac transthyretin amyloidosis
2021-003674-32Phase 2Completed
- Sponsor
- Region Västerbotten
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dapagliflozin in amyloid cardiomyopathy, sponsored by Region Västerbotten. Primary endpoint: NT-proBNP change. Started Oct 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
amyloid cardiomyopathy
Beyond the preview
Go deeper on 2021-003674-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003674-32.